

From: Scott Ford <pharma@smiconferences.co.uk>
To: Kester, Tonykester@aging.sc.gov
Date: 8/1/2016 9:42:30 AM
Subject: National Action Plans Against Antibiotic Resistance | Updates from PAHO/WHO, NIAID, BARDA

Additional Speakers Include: **John Rex**, Senior VP and Chief Strategy Officer from the Infectious Disease Unit at AstraZeneca
+ more...

Superbugs & Superdrugs USA

Conference: Nov 14th & 15th

Workshops: Nov 16th - 2nd exciting new workshop to be released soon...details to follow

Renaissance Woodbridge Hotel, Iselin, New Jersey

Proudly Sponsored by Polyphor

[Register](#) | [Agenda](#) | [Contact us](#)

IN THE NEWS: 2nd Case of MCR-1 Superbug found in North America

ATTENDEE LIST: Take a look at our growing community of antimicrobial experts by downloading the previous [list of attendees](#) from our European show

Dear Mr Tony Kester,

Resistant to colistin – an antibiotic often referred to as the "last line of defense", the **MCR-1 superbug gene** first started making headline news last year when it was discovered in an isolated case in China, researchers have since discovered infected patients from Canada, Europe, and more recently, North America. Its reported ability to transmit from one species to another, could increase the risk of new strains of bacteria developing that are resistant to all antibiotics.*

SMi's [Superbugs & Superdrugs USA](#) conference will showcase **4 key spotlight sessions** on the national plans and clinical advances in fighting drug resistant bacteria.

Below is just a snap shot of what to expect at the industry leading series. [Visit the website](#) to see a **detailed agenda** and full speaker line-up by downloading a brochure today.

1. Public and Private Partnership

Learn about progress in the development of National Action Plans with exclusive presentations from **PAHO/WHO, NIAID** and **BARDA**. This unmissable session will bring together senior officials from federal agencies to provide unique insight into:

- Strategic lines of action
- NIAID and national strategy for CARB (Combating Antibiotic Resistant Bacteria)
- BARDA's end-to end support of antibacterial product development

Highlights also include a keynote address by **John Rex**, Senior VP and Chief Strategy Officer from the Infectious Disease Unit at **AstraZeneca**.

Register now to take advantage of the **\$300 earlybird saving**.

2. Research and Development Updates

How can gram-positive antibiotics be turned into **gram-negative therapeutics**? What progress has been made towards **developing vaccines** for the prevention of Staphylococcus aureus infections? How can antibiotic sensitivity in **multi-drug resistance** be restored?

These will be just some of the questions addressed surrounding industry developments in antibiotic drug discovery through case study insight from big pharma and biotech such as **Pfizer**, **Blueberry Therapeutics** and **Spero Therapeutics**.

View the full speaker line-up.

3. Novel Antibacterial Therapeutic Approaches

Stay at the forefront of cutting edge progress by discovering innovative approaches to antibacterial therapy. The packed session opens with a keynote address by Dr Anthony Simon Lynch, Senior Scientific Director from **Janssen Research & Development**.

Topics covered include novel protein based biologics, antibody drug conjugates, combination therapy, plus much more!

Take a look at the detailed conference agenda.

4. Strengthening the Pipeline

Evolve your pipeline with medical guidance into restoring antimicrobial activity of a variety of B-lactams against multi-drug resistance gram-negative pathogens. The spotlight on reinforcing the antibiotic drug portfolio, will highlight collaborative development of novel drugs through a European case study and showcase opportunistic approaches for the treatment and prevention of microbial infections.

View full details

How to Register:

Register now to take advantage of the \$300 early bird saving at:
www.superbugs-usa.com

Sponsorship Enquiries:

Reach your target audience by becoming a sponsor:
For sponsorship and exhibitor packages, contact Alia Malick on
+44 (0)20 7827 6168 or email amalick@smi-online.co.uk

Delegate Enquires:

For delegate enquiries, group bookings and pharma rates,
contact Matthew Apps on +44 (0)20 7827 6093 or
email mapps@smi-online.co.uk

Special discounts available for registering onto all 3 days!

Get in touch for further details.

* Source: <http://bit.ly/29NMysn>

You are registered as: kester@aging.sc.gov Your Unique Reference Number: 92804565
To update your contact preferences please go to <http://www.smi-online.co.uk/update-preferences>